Critical Pharmacodynamic Warning
clobazam affects the 2C19 metabolic pathway.
When patients take clobazam concurrently with drugs metabolized by 2C19, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.
Clinical Impact: As a under review, clobazam can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.
Clinical Overview for clobazam
This page outlines known interaction pathways involving clobazam, focusing primarily on its profile as a under review affecting the 2C19 pathway.
Enzyme Interaction Profile
clobazam demonstrates under review potency against 2C19. Clinical significance of this interaction requires further evaluation.
Inhibitor
A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.
Clinical Example: clobazam affects 2C19Inducer
A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.
Interaction Details
| Drug Name | clobazam |
| Affected Enzyme | 2C19 |
| Inhibitor Strength | under review Under Evaluation |
| Inducers | No inducers listed |
| Inhibitors | topiramate |
Clinical Recommendations
Clinical significance pending review. Exercise caution.
- Therapeutic drug levels
- Adverse effect monitoring
- Clinical response assessment
- Consider dose reduction
- Evaluate alternative therapies
- Adjust based on response
Quick Facts
12875
2C19
Enzyme Inhibition
Under Evaluation
Clinical Significance
Clinical significance requires further evaluation.
Information Sources
- FDA Drug Interaction Database
- Clinical Pharmacology Guidelines
- Pharmaceutical Labeling Information
- Published Clinical Studies
Last updated: June 16, 2026